ReviewGene therapy2013
Zinc finger nucleases: looking toward translation.
Review in Gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The ethics of clinical applications of germline genome modification: a systematic review of reasons.Human reproduction (Oxford, England) · 2018Pooled it
- Genetic Improvement of rice Grain size Using the CRISPR/Cas9 System.Rice (New York, N.Y.) · 2025Review
- Advances and applications of genome-edited animal models for severe combined immunodeficiency.Zoological research · 2025Review
- Genome Editing Approaches Using Zinc Finger Nucleases (ZFNs) for the Treatment of Motor Neuron Diseases.Current pharmaceutical biotechnology · 2025Review
- CRISPR/Cas-based CAR-T cells: production and application.Biomarker research · 2024Review
- Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.Stem cells translational medicine · 2024Review
- Recent Developments in CRISPR/Cas9 Genome-Editing Technology Related to Plant Disease Resistance and Abiotic Stress Tolerance.Biology · 2023Review
- Corneal gene therapy: Structural and mechanistic understanding.The ocular surface · 2023Article
- Review: Recent Applications of Gene Editing in Fish Species and Aquatic Medicine.Animals : an open access journal from MDPI · 2023Review
- Genome editing technologies, mechanisms and improved production of therapeutic phytochemicals: Opportunities and prospects.Biotechnology and bioengineering · 2023Review
- Methods of crop improvement and applications towards fortifying food security.Frontiers in genome editing · 2023Review
- Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States.BMC medical ethics · 2022Article
- The Current Status of Gene Therapy for the Treatment of Cancer.Biologics : targets & therapy · 2021Review
- Modulating gene regulation to treat genetic disorders.Nature reviews. Drug discovery · 2020Review
- Viable Mice with Extensive Gene Humanization (25-kbp) Created Using Embryonic Stem Cell/Blastocyst and CRISPR/Zygote Injection Approaches.Scientific reports · 2018Article
- Nanotechnology for delivery of peptide nucleic acids (PNAs).Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Recent developments and clinical studies utilizing engineered zinc finger nuclease technology.Cellular and molecular life sciences : CMLS · 2015Review
- The ethics of HIV "cure" research: what can we learn from consent forms?AIDS research and human retroviruses · 2015Article
- State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.Discovery medicine · 2014Review
- Zinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic engineering has emerged as a powerful mechanism for understanding biological systems and a potential approach for redressing congenital disease. Alongside, the emergence of these technologies in recent decades has risen the complementary analysis of the ethical implications of genetic engineering techniques and applications. Although viral-mediated approaches have dominated initial efforts in gene transfer (GT) methods, an emerging technology involving engineered restriction enzymes known as zinc finger nucleases (ZFNs) has become a powerful new methodology for gene editing. Given the advantages provided by ZFNs for more specific and diverse approaches in gene editing for basic science and clinical applications, we discuss how ZFN research can address some of the ethical and scientific questions that have been posed for other GT techniques. This is of particular importance, given the momentum currently behind ZFNs in moving into phase I clinical trials. This study provides a historical account of the origins of ZFN technology, an analysis of current techniques and applications, and an examination of the ethical issues applicable to translational ZFN genetic engineering in early phase clinical trials.
Indexed as
Identifiers
22318089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.